Year: 2025
Type: preprint
Abstract: Bispecific antibodies (BiAbs), which can simultaneously bind two distinct antigens, have emerged as a promising therapeutic strategy for treating cancer, autoimmune disorders, and metabolic diseases. The United States, China, and Europe are the leading regions in BiAb research, each demonstrating unique strengths. The United States dominates the field with a mature research ecosystem and balanced progression across all stages of development. China excels in early-stage innovation but continues to face challenges in late-stage clinical trials and commercialization. Europe emphasizes high-quality foundational research, although its overall output remains limited. Key research targets include PD-1 x CTLA-4 and CD3-based combinations, underscoring BiAbs pivotal role in immunotherapy. The BiAb research reveals significant disparities in regional priorities, technological capabilities, and developmental progress, which collectively shape innovation and translational outcomes in this field. These variations highlight differences in research intensity, infrastructure quality, and regulatory frameworks that critically influence the advancement and outcomes of BiAb development globally.
Authors: Yuxuan Gong, Zetong Wu, Jinglan Huang, Xiaotong Yang, Dan Wang, Sirong He
Institutions: University of Leicester, Chongqing Medical University
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4413370594